CoChat

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

OBJECTIVE: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have lately become the recommended treatment in patients with type 2 diabetes and high cardiovascular risk. Patients with posttransplant diabetes mellitus (PTDM) also have high cardiovascular risk. The aim of this study was to investigate the safety and efficacy of empagliflozin in renal transplant recipients with PTDM. RESEARCH DESIGN AND METHODS: Forty-nine renal transplant recipients were included in an investigator-initiated, single-center, prospective, double-blind study and randomized to receive either 10 mg empagliflozin or placebo once daily for 24 weeks. Patients transplanted >1 year ago, diagnosed with PTDM, with stable renal function (estimated glomerular filtration rate [eGFR] >30 mL/min/1.73 m2), and with stable immunosuppressive therapy were studied. RESULTS: Forty-four renal transplant recipients (22 empagliflozin/22 placebo, 34 males) completed the study. Median (interquartile range) change in glycated hemoglobin (HbA1c) was significantly reduced with empagliflozin compared with placebo: −0.2% (−0.6, −0.1) (−2.0 mmol/mol [−6.5, −1.0]) vs. 0.1% (−0.1, 0.4) (1.0 mmol/mol [−0.75, 3.8]) (P = 0.025). The magnitude of glucose reduction was dependent on GFR and baseline HbA1c. The treatment also resulted in a significant reduction in body weight of −2.5 kg (−4.0, −0.05) compared with an increase of 1.0 kg (0.0, 2.0) in the placebo group (P = 0.014). There were no significant differences between the groups in adverse events, immunosuppressive drug levels, or eGFR. CONCLUSIONS: Empagliflozin appeared safe and improved glycemic control in renal transplant recipients with PTDM compared with placebo. A concomitant reduction in body weight was seen.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-0093

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 37 · Cited by 231

Metadata

Authors
Halden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T.
Affiliations
  • Oslo University Hospital (NO)
  • University of Oslo (NO)
  • University Hospital of North Norway (NO)
Corresponding author
Kvitne, Kine Eide
Venue
Diabetes Care
Published
2019-03-12
Volume
42
Issue
6
Pages
1067-1074
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2921909972
Cited by
231
References
37
Citations by year
2026: 36 · 2025: 39 · 2024: 27 · 2023: 34 · 2022: 31 · 2021: 36 · 2020: 22 · 2019: 6
FWCI
19.23
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
Funders
Boehringer Ingelheim, Norway
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
empagliflozin, SGLT2 inhibitors, post-transplant diabetes mellitus, kidney transplant recipients, glycemic control, HbA1c, weight loss, immunosuppressive therapy, drug safety, estimated glomerular filtration rate
MeSH terms
Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Postoperative Complications, Kidney Transplantation, Treatment Outcome, Renal Insufficiency, Chronic, Young Adult, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. https://app.cochat.ai/papers/10.2337/dc19-0093
The paper
Halden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019). Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. https://doi.org/10.2337/dc19-0093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.